Dechra Pharmaceuticals | DPH


Peers Price Chg Day Year Date
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
IQVIA Holdings 187.68 3.60 1.96% -22.83% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05


Dechra Pharmaceuticals traded at 3,866.00 this Tuesday January 16th. Looking back, over the last four weeks, Dechra Pharmaceuticals lost 0.52 percent. Over the last 12 months, its price rose by 32.40 percent. Looking ahead, we forecast Dechra Pharmaceuticals to be priced at 3,845.12 by the end of this quarter and at 3,783.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company’s segments include European Pharmaceuticals, NA Pharmaceuticals, and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment comprises of Dechra Veterinary Products EU, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing & Supply. This Segment operates internationally and manufactures and markets Companion Animal Products (CAP), Equine, Food producing Animal Products (FAP) and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Dechra Veterinary Products Canada, and Dechra Productos Veterinarios (Mexico), which sell CAP, Equine and FAP in those territories. The Segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas. The Pharmaceuticals Research and Development Segment includes all of the Company's pharmaceutical research and development activities.